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Abstract:
Background: Catechol, 1,2-dihydroxybenzene, prepared through bacterial biotransformation
from higher order polyphenols, has been proposed to regulate carbohydrate metabolism, especially
in the context of type 2 diabetes. This review aims to contextualize this finding. It describes the
bacterial biosynthesis of catechol both from glucose, and as a degradation product of higher order
natural products through bacterial transformation. The review then considers the mechanism of
action of glycemic-regulating catechol-containing materials and the complications arising from
balancing their inherent activity with that of catechol, their common degradation product. It then
enumerates potential dietary sources of catechin from common foods.
Methods: Articles were found through using a combination of key word searches in Pubmed, Web
of Science, and Scifinder, coupled with following relevant references in those articles, and tracking
the articles that cite them. This is not a systematic review, so only those references germane to the
specific needs of the review were included.
Results/Conclusion: Catechol is a potentially promising metabolite for modulating metabolism,
but the sources of the catechol themselves mediate glucose homeostasis through a number of
competing mechanisms. The levels of catechins is quite low in most dietary foods with the
exception of cocoa, chicory, and green tea. Catechin-rich green tea might prove a useful dietary
supplement to work with a catechol-producing probiotic; however, further studies are required to
determine the physiological relevance of this approach.
Key words: Diabetes, biotransformation, insulin sensitization, microbiome, symbiosis, probiotic.
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Introduction
This review arose out of our interest in exploring in situ biotransformation as a possible minimally
interventionist complementary treatment for disease. Catechol and the catechins have been
suggested as a potential nutraceutical approach towards moderating type 2 diabetes insulin
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desensitization. It is readily obtained from the bacterial biotransformation of very common, more
complex, plant secondary metabolites, by certain benign gut symbionts. Although the overall
effects of the biotransformation are well understood, they have not been synthesized into a unified
report that summarizes the field from a biochemical perspective; this is that review. The scope
includes a very brief overview of current Type 2 Diabetes treatments with a focus on current nonpharmaceutical chemical interventions; catechol biosynthesis from glucose, and its preparation as
a byproduct during the metabolism of higher order catechins and similar materials; the rationale
for its potential use to treat diabetes; an annotated list of catechol-rich foods organized by
derivative present; and a critical analysis of the current state of knowledge regarding the complex
interplay of these different components on the regulation of mammalian carbohydrate metabolism.
We conclude with a synthesis including recommendations for future avenues of investigation that
might prove fruitful. For readers more interested in the biotransformation of these molecules by
human cells, rather than the biotransformation by gut microflora, we direct them instead to several
excellent reviews surveying epicatechin,[1] catechin,[2] and wine phenolics more generally.[3]
1. Type 2 Diabetes and Insulin Desensitization
1.1 Pathology and Epidemiology of type 2 Diabetes
Non-insulin dependent diabetes, type 2 diabetes (T2D), is a chronic condition that affects everincreasing millions of people worldwide.[4] Responsible for 90-95% of all diabetes cases globally,
it is characterized by interruptions of the insulin receptor signaling pathway.[5] This is in contrast
to type 1 diabetes (T1D), an autoimmune disease where the insulin producing β-cells in the
pancreas are attacked, causing an absolute insulin deficiency.[5]
The insulin signaling pathway is the fundamental mechanism for maintaining glucose homeostasis,
and the loss of control over glucose production and storage generates a hyperglycemic state (Figure
1).[6] This leads to preliminary symptoms including increased thirst, increased urination, blurry
vision, and a numbness of hands and feet. Disease progression can cause more serious
cardiovascular symptoms, such as atherosclerosis, and can eventually lead to a coma, and death.
T2D typically emerges as a consequence of obesity or a higher-than-average body fat percentage.
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Diet control, weight loss and physical activity are unquestionably the best ways to treat the
disease.[7] However, depending on severity, many patients also require oral antidiabetic
medications to manage symptoms. The biguanides, primarily metformin, are commonly
prescribed, although, they come with a variety of undesirable side-effects, including
hypoglycemia, vitamin deficiency, neuropathic and gastrointestinal symptoms.[4, 8-11] These
side-effects are particularly pronounced in the elderly and metformin has been shown to exacerbate
other conditions as well, such as Alzheimer’s disease.[12] Alternative treatments, potentially able
to assist and consequently reduce the dosage of these medications, could reduce the burden of

these side effects.
Figure 1: Cartoon illustrating the long-term outcomes of type T2D. Image prepared with
BioRender.

1.2 Alternatives to current oral medications
Alternative therapeutic approaches involving lifestyle changes that lack detrimental off-target
effects are increasingly reported in the literature, such as acupuncture, hydrotherapy, and yoga.[1315] With the caveat that most synthetic drugs are derived from a natural product scaffold, whole
plants have also been looked at as a source for potential hypoglycemic drugs, where the synergistic
action of multiple active ingredients in a complex matrix are often challenging to characterize and
understand.[16] One promising class of materials are phenolic secondary metabolites,[17, 18]
likely acting partially through an antioxidant mechanism, although they have also been proposed
to provide antidiabetic activity through inhibiting intestinal glucose uptake, increasing insulin
secretion and sensitivity, and regulating intracellular signaling.[19, 20] It is important to note that
flavanols may not act as antioxidants but instead through modulating cell signaling cascades to
5

have these beneficial effects.[21] The antioxidant activity of these materials will also, generally,
be rather small compared with the omnipresent antioxidant vitamins, but noted marginal
improvements in outcomes are intriguing. Nachar and colleagues have demonstrated that the
increase in dietary phenols associated with Serratia vaccinia fermentation of blueberry juice
stimulates glucose uptake in insulin sensitive cells and decreases hepatocellular glucose output.[6]
Catechol demonstrated the greatest anti-diabetic activity of the resulting metabolites in the
glucose-6-phosphatase inhibition assays (Table 1).[6] Their in vivo studies demonstrated that
catechol supplementation improves two major factors associated with T2D control: a decrease in
hepatocellular glucose output and an increase in muscle glucose uptake. No specific mechanism
by which this occurs was proposed. It is unclear from their work if the catechol survives
unchanged, or is, more likely, converted to a conjugate for transport.
Table 1: Anti-diabetic effects of various catechols, information sourced from Nachar et al.[6]
Compound

G6Pase activity decrease (%)

Enhancement of glucose uptake (%)

Catechol

54

43

Chlorogenic acid

-

15

Gallic acid

25

16

Protocatechuic acid -

-

The catechol moiety is most effective for insulin sensitization when present as either the isolated
compound or present in catechin, compared to being incorporated into other compounds.[6, 22] In
fact, when present in catechol estrogens or catecholamines, the effect appears to be reversed,
potentially due to direct interaction of these molecules with the insulin receptor (vide infra).[23,
24] No clinical studies have yet been conducted to date on catechol’s bioactivity, although this has
been proposed as a potentially fruitful intervention. This review lays the groundwork of catecholcontaining endogenous and exogenous compounds for future studies and supporting data to date.
2. The biochemistry of catechol
2.1 Catechol is biosynthesized from glucose
Catechol (C6H6O2), also referred to as pyrocatechol or 1,2-dihydroxybenzene, is a natural phenolic
compound. It is found in trace amounts in fruits and vegetables and more substantially in fermented
6

berry juices, usually biosynthesized from glucose.[25]-[26, 27] It is synthetically manufactured
from fossil fuels for uses from perfumes to pesticides.[28] The catechol group is incorporated into
many natural products including catechins, catechol estrogens, and catecholamines such as
dopamine and epinephrine (Figure 2), and is often generated as a byproduct of their metabolism
where it can act as a potent antioxidant.[29-31] Catechol is prepared through the 3-dehydroquinate
pathway which generates the carbasugar-related 3-dehydroshikimic acid (Figure 3). This is then
aromatized and decarboxylated to provide the diphenol.

Figure 2: Catechol and examples of catechol-containing compounds.
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Figure 3: The biosynthesis of catechol from glucose.12

2.2 Catechin Breakdown to Catechol
Catechins are flavan-3-ols, a subclass of flavonoids.16 These are natural products containing
phenolic groups,[32] commonly found in teas, fruits, lentils, and nuts.[33] Catechins have
demonstrated antioxidant capabilities and have been shown to have positive impacts on
cardiovascular health.[34]
Many microbes have a demonstrated ability to degrade catechin. This includes the fungi
Chaetomium

cupreum,[35]

Aspergillus

fumigatus,

Penicillium

freguentus,

Penicillium

janthinellum, and Fusarium sp;[36] however it is a more common capability in bacteria such as
Rhizobium sp.,[37] Pseudomonas sp.,[38] and Acintobacter sp.[39], as well as gut microbes such
as Lactobacillus sp.[40] Other gut microbiome bacteria such as Lactobacillus plantarum IFPL935,
Enterobacter aerogenes, Raoltella planticola, Klebsiella pneumoniae susp. pneumoniae, and
Bifidobacterium longum subsp. infantis have been shown to metabolize catechins.[41, 42] As a
carbon feedstock for this many species, it is unsurprising that catechin metabolism can occur via
8

multiple different biochemical pathways, only some of which provide catechol, possibly due to
convergent evolution to use this carbon source. A primary pathway, utilized by P. solanacearum
and Rhizobium sp., oxidatively cleaves catechin to protocatechuic acid which then decarboxylates
to catechol (Figure 4A). However, different bacteria use different methods; C. cupreum uses an
oxidative cleavage that generates a mixture of catechol and protocatechuic acid along with
pholoroglucinol carboxylic acid from the other side of the molecule (Figure 4B). These are then
further degraded to acetaldehyde and pyruvic acid; P.solanacearum has been proposed to use two
parallel pathways to break down both sides of the molecule to β-ketoadipate, losing only two
equivalents of carbon dioxide in this atom efficient process (Figure 4C).
As they play an essential role in the health and maintenance of the human gut microbiome,
lactobacilli strains may be exploitable for their potential to degrade catechin into potentially
beneficial natural molecules.[43] A recent study identified as a potential candidate for catechin
biotransformation.[40] For example, Lactobacillus hilgardii, isolated from red wine, efficiently
converts catechins to catechols and other phenols such as gallic acid, pyrogallol, phydroxybenzoic acid, acetovanillone, and homovanillic acid.[40] However, the enzymology
remains uncharacterized in Lactobacillus, one of the most promising and commercially relevant
species. This would be a useful addition to the literature.
2.2.1 Enzymology of Catechin Conversion to Catechol
Enzymes have been implicated in the breakdown of catechin to catechol in select eukaryotes but
not yet in prokaryotes. In yeasts, catechin oxygenase cleaves catechin to release protocatechuic
acid in Chaetomium cupreum, Pencillium spp. and Aspergillus spp.[44] However, not all
prokaryotes can naturally break down catechin. Boominathan and Mahadevan showed that this
process can be induced through the introduction of a plasmid, pAMB1 from Enterococcus faecalis
a competent species.[38, 45] The authors studied Psuedomonas solanacearum, a bacterium
generally unable to process catechin, but the introduction of the plasmid with an unspecified
catechin-associated gene cluster, was able to facilitate the complete metabolism of the natural
product. Defining this biochemistry is still ongoing as alternative enzymes, including catechol
dioxygenases as found in Rhizobium sp.,[46] Penicillium spp, Aspergillus spp, Chaetomium sp.
[44] and Acintetobacter sp. [39] can also be involved. In these species, a decarboxylase finishes
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the degradation to furnish catechol. This variety of pathways will provide alternatives for future
biotechnological or probiotic engineering.
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Figure 4. A) Proposed pathway for the degradation of catechin by P. solanacearum [38] and
Rhizobium sp. [37]; B) Proposed degradation pathway in Cheatomium cupreum [35]. C) Proposed
pathway for the degradation of catechin by Psuedomonas solanacearum with an introduced
plasmid from Enterococcus faecalis.[38]

3. Potential Probiotic Usage
Nutraceuticals have always been used by the global population, but there is increasing focus to
provide a scientific rationale to either support or highlight contraindications for their use for
specific medical purposes. Catechols and polyphenols more generally have potent antioxidant
potential.[47, 48]-[49] For example, many of the touted health benefits of green tea are likely due
to the presence of catechin.[50, 51] With these high levels in a common beverage (rather than an
expensive and obscure product such as blueberry juice), catechol therapy could realistically be
achieved through a Lactobacillus probiotic vehicle. This would allow for the steady biogeneration
of catechol, which might benefit diabetics. However, in order to make this a reality, more suitable
bacterial species must be identified and explored such as those within the genus Lactobacillus,
native to the gut microbiome and with other species established to be capable of catechin
biotransformation to catechol.[40] Exposing various human gut microbes, including Lactobacillus,
with a fractionated grapeseed juice sample containing high catechin levels, produced postfermentation products with a significant level of catechol. There was no detectable catechol prior
to juice fermentation.[52] Lactobacillus are one of the predominant probiotics, and are commonly
found in dairy products and fermented foods.[53] They have been reported to provide a variety of
health benefits when delivered in a targeted manner, including the prevention of gastrointestinal
disease and immune system modulation [54]. Their use as in situ bioreactors to deliver therapeutics
has already been demonstrated.[55] Lactobacilli have been used to biotransform phenylalanine and
isoflavone phytoestrogen to more bioactive compounds.[56, 57] They are a likely candidate for
microbiome generation of catechol in the gut of those with diabetes, in addition to the several
different microbes discussed in section 2.2 of this review.
Catechin degradation has been shown to occur in mammalian guts, including humans[58] and
guinea pigs.[59] A more thorough study has been conducted in a pig, a useful model as the pig
cecum microbiota composition is similar to that of humans for most bacterial species.[60] The
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suggested pathway of metabolism of (+)-catechin in both guinea pig and human cells does not pass
through catechol or its intermediates;[58, 59] however, cytochrome-mediated oxidative processes
in the liver follow a general oxidative cleavage which converts catechin into protocatechuic acid
as shown in Figure 4A, that can breakdown into catechol. This human-cell metabolism is also only
of limited interest, as most biotransformation would occur in bacteria in the gut, and these almost
universally use catechol as the terminal product. However, for any of this to be relevant, the diet
would need to be rich in catechins, and this requires an understanding of the catechin and related
compound composition in various foods.
3.1 (Poly)phenolic Rich Food Sources
Key foods that are rich in pro-hypoglycemic catechols typically include fruits, teas, and other
vegetable sources (Table 1 and 2). Some sources have quantified the catechin, epicatechin, and
protocatechuic acid content in the food (Table 1 and 2). For more general discussions of flavan-3ols and their dietary prevalence and biochemistry, please see reviews by Nishiumi and
coworkers,[61] a very recent review on phenyl-γ-valerolactones and phenylvaleric acids by Mena
and co-authors,[62] and the foundational review by Aron and Kennedy on flavan-3-ols.[63] We
propose that green tea offers a particularly simple medium for the analysis of catechin
biotransformation as the low sugar environment limits alternative carbon sources.

Table 1. Catechin and epicatechin content of common foods.
Source

Apple (Granny Smith)
Apple (Golden Delicious)
Apricot
Blackberry
Black Grape
Nectarine
Peach
Plum
Strawberry
Albert Heijn Chocolate - Black
Albert Heijn Chocolate - Milk
Mars Bar

(+)catechin
Amount
16 mg/kg
5.3 mg/kg
50 mg/kg
6.6 mg/kg
89 mg/kg
27 mg/kg
23 mg/kg
34 mg/kg
45 mg/kg
130 mg/kg
38 mg/kg
22 mg/kg

75 mg/kg
74 mg/kg
61 mg/kg
180 mg/kg
86 mg/kg
NDa
NDa
28 mg/kg
NDa
330 mg/kg
120 mg/kg
63 mg/kg

Raisins
Rhubarb

30 mg/kg
22 mg/kg

7.1 mg/kg
5.1 mg/kg
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(-)-epicatechin
Amount

Ref.

[64]

Serving size (catechin; epicatechin,
per serving)
113 g (1.9 mg; 8.5 mg)[65]
113 g (0.6 mg; 8.5 mg)[65]
150 g, two apricots (7.5 mg; 9.1 mg)
101 g (0.6 mg; 18.2 mg)[65]
83 g (7.4 mg; 7.1 mg)[65]
140 g (3.8 mg; ND)
97 g (2.23 mg; ND)[65]
112 g (3.8 mg; 3.2 mg)[65]
103 g (4.6 mg; ND)[65]
100 g (13 mg; 33 mg)[66]
100 g (3.8 mg; 12 mg)[66]
58 g (1.3 mg; 3.7 mg)[66]
31 g (0.9 mg; 0.2 mg)[65]
106 g (2.3 mg; 0.54 mg)[65]

Lotus leaf (Nelumbo nucifera)
ga

15 mg/g

NMb

[67]

60g (0.9 mg; NM)

ND = none detected; b NM = not measured

Table 2. Protocatechuic acid content of various foods.
Source

Amount

Reference

Serving size (protocatechuic acid/serving)

Apple

4.8 mg/kg

[68]

113 g (0.5 mg)[65]

Gooseberry

62 mg/kg

150 g (9.3 mg)

Raspberry

42 mg/kg

107 g (4.5 mg)[65]

Strawberry

17 mg/kg

103 g (1.8 mg)[65]

Currants, black

12-55 mg/kg

[68, 69]

39 g (0.5-2.1 mg)[65]

Avocado

0.37 mg/kg

[70]

30 g (0.011 mg)[71]

Blackberries
Mulberries, black

20 mg/kg
18 mg/kg

[69]

101 g (2.0 mg)[65]
101 g (1.8 mg)

Cauliflower

4.5 mg/kg

[72]

81 g (0.36 mg)[65]

Chicory

170-220 mg/kg

[73]

30 g (5.1-6.6 mg)

Dates, dried

49 mg/kg

85 g (4.2 mg)[65]

Olive, black, raw

60 mg/kg

20 g (1.2 mg)[74]

Olive, green, raw

6.6 mg/kg

20 g (0.13 mg)[74]

Wine, red

40-100 mg/kg

Wine, white

10-70 mg/kg

Kiwifruit

1.5 mg/kg

Muskmelon, white pulp

13 mg/kg

150 g (2.0 mg)[71]

Muskmelon, yellow pulp

8.9 mg/kg

150 g (1.3 mg)[71]

[75]

150 g (6.0-15 mg)[76]
150 g (1.5-10.5 mg)[76]

[77]

52 g (0.08 mg)[65]

Unlike its precursors, there is little information regarding the catechol content in specific food
sources. However, it is present in onions, chicory, grapefruit, strawberries, olives, oregano,
avocado, cacao, and vanilla.[78] It is also found in trace amounts in many other fruits and
vegetables and in many fermented berry juices and wines.[26, 27]

4. Known Effects of Catechols on Carbohydrate Metabolism
The catechol moiety, generally arising from tyrosine hydroxylation, is incorporated into a number
of human endogenous hormones, neurotransmitters, and other effectors.[79] These molecules play
essential regulatory roles in many biological pathways with varying systemic effects; those
affecting carbohydrate metabolism are summarized in Table 3 and 4. A number of endogenous
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catechols reportedly suppress insulin receptor signaling and consequently reduce glucose uptake,
while others increase glucose uptake (decreasing serum glucose levels).
4.1 Pro-hyperglycemic catechols
4.1.1 Catecholamines
The numerous members, often nervous or endocrine system effectors, of this family conserve
dopamine’s structure (Figure 5). Many catecholamines – but not all – signal through adrenergic
receptors, which are antagonistic to insulin signaling, and result in lowered blood glucose, and
activate carbohydrate anabolism.[79] The α1-adrenergic receptors trigger gluconeogenesis and
glycogenolysis in liver,[80] while the β2-adrenergic receptors also trigger glycogenolysis in both
liver and skeletal muscle [81], as well as gluconeogenesis in liver.[80] Agonistic ligands for α1adrenergic receptors containing the 3,4-dihydroxyphenethylamine structure include the
endogenous norepinephrine (7) and epinephrine (8),[82] and the synthetic isoprenaline (9).
Endogenous agonists for β2-adrenergic receptors containing the 3,4-dihydroxyphenethylamine
structure include epinephrine and norepinephrine.[83] This is clearly a core moiety for receptor
interaction as the synthetic antagonists for α1-adrenergic receptors contain catechol diether
moieties – where both catechol oxygens have been alkylated – but do not contain the full 3,4dihydroxyphenethylamine structure common to many adrenergic agonists, instead generally
incorporating the nitrogen into a heterocycle or amide bond; these include alfuzosin (15), silodosin
(16), doxazosin (17), tamsulosin (18), prazosin (19), and terazosin (20, Figure 6). The nonselective β-blockers carvedilol (21) and oxprenolol (22) similarly include dialkylated catechols. It
must be considered, however, that although β-blockers do inhibit adrenergic signaling, they
themselves can induce glucose intolerance as the body responds to their presence.[84]
Activation of the α2-adrenergic receptors – whose ligands include epinephrine, norepinephrine,
and isoprenaline – induces glucagon release from the pancreas.[85] Glucagon will subsequently
itself trigger glycogenolysis and gluconeogenesis via interaction with its own receptor,[86]
potentially further amplifying glucose mobilization of the α1- and β2-adrenergic receptors.
However, as with the α1- and β2-adrenergic receptors, the α2-adrenergic antagonists idazoxan (13)
and piribedil (14) both contain catechol cyclic diether moieties (Figure 5). These three prohyperglycemic
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adrenergic

receptors

are

consequently

all

agonized

by

the

3,4-

dihydroxyphenethylamine catecholamine structure and antagonized by alkylated catechol
congeners.
While the 3,4-dihydroxyphenethylamine structure is common to many α1- and β2-adrenergic
agonists, dopamine (10) itself is not a potent agonist of these receptors. Instead, dopamine has its
own receptors: the D1 through D5 receptors,[87] and trace-amine associated receptor 1
(TAAR1).[88] In contrast to the adrenergic receptors, the dopaminergic receptors are not generally
implicated in the regulation of blood glucose; nonetheless, several tantalizing hints prove
interesting. Pro-hyperglycemic properties have been reported in dopamine precursor, levodopa (LDOPA, 11).[89] The precursor elicited synergistic pro-hyperglycemic properties when combined
with carbidopa (12)– a synthetic inhibitor of DOPA decarboxylase designed to increase L-DOPA
half-life – as evidenced by diminished glycogen concentrations, decreased glycogen synthase
activity, and reduced insulin-stimulated glucose transport in rat skeletal muscles [90].
Interestingly, however, D2 receptor signaling suppresses norepinephrine secretion and growth
hormone (GH) secretion, both of which would lead to downstream increases in blood glucose.[91]

Figure 5. Pro-hyperglycemic catecholamines and α2-adrenergic antagonists.
15

Figure 6. Synthetic antagonists for α1-adrenergic receptors.

4.1.2 Tyrphostins (pro-hyperglycemic)
The tyrosine phosphorylation inhibitors, or tyrphostins, are a family of small molecule competitive
inhibitors of receptor and non-receptor tyrosine kinases; many tyrphostins contain catechol
moieties given their structural similarity to the tyrosine side-chain (Figure 7). Given the
pervasiveness of tyrosine kinases in signaling pathways that regulate proliferation, survival,
growth, and metabolism[92, 93], it is unsurprising that tyrphostins have varying target-dependent
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effects on glucose uptake and metabolism, and receptor selectivity can be tuned through apparently
minor structural adjustments.
AG-538 (24) is a synthetic dicatechol which bind,s as an antagonist, to the active site of the
tyrosine kinase insulin-like growth factor 1 (IGF-1) receptor, preventing the autophosphorylation
that is induced by IGF-1 binding.[94] This is relevant to glucose regulation as IGF-1 deficiency is
correlated to elevated insulin resistance. In fact, due to its structural homology to insulin, IGF-1
has been shown to bind insulin receptors in fat and muscles cells and stimulate glucose
transport.[95] How antagonism of the IGF-1 receptor affects IGF-1 levels and their interaction
with the insulin receptor has not yet been explored.
Closely related tyrphostins A47 (25) and B46 (26) are inhibitors of the GLUT1 hexose transporter,
but differ in molecular mechanism.[96] B46 interacts with the external surface of the GLUT1
transporter, while A47 enters the cell and interacts with the cytoplasmic surface. Binding of either
molecule to their respective sites induces an unfavourable conformational change in the GLUT1
transporter, inhibiting its ability to transport glucose into the cell. Although the experimental data
suggests a competitive mechanism of inhibition, the possibility of the tyrphostins binding to an
alternate site cannot be ruled out, and the crystal data is slightly suspicious as the structures are so
similar. It is still possible that either ligand can bind to either site.

Figure 7. Pro-hyperglycemic synthetic Tyrphostins.

Table 3. Pro-Hyperglycemic Catechol-Containing signaling molecules
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Catechol-containing Compound
Norepinephrine

Epinephrine
Isoprenaline
Dopamine
Levodopa & Carbidopa
Tyrphostin A47
Tyrphostin B46
Tyrphostin AG538

Effect on carbohydrate metabolism
- adrenergic receptor binding
- decreased insulin sensitivity
- decreased binding affinity [97]
- adrenergic receptor binding
- increased glucagon secretion[98]
- decreased glucose transport[99]
- elevated glucose levels [89]
- enhanced glycogen phosphorylase activity
- decrease glycogen synthase activity
- adrenergic receptor binding [90]
- GLUT1 hexose transporter inhibitor
- cytoplasmic binding [96]
- GLUT1 hexose transporter inhibitor
- external cell binding [96]
- competitive inhibitor of IGF-IR receptor [94]

4.2 Pro-hypoglycemic catechols
While some catechol-containing molecules decrease insulin sensitivity and glucose uptake,
utilization and storage, others contrastingly decrease glycemic load. These include catechol itself,
catechin, and several intermediary metabolites involved in the conversion of catechin to catechol.
These pro-hypoglycemic combined effects are likely observed in complex dietary mixtures, such
as teas and wines, and are the desired effects of catechol supplementation.
4.2.1 Catechin & Flavan-3-ol Monomers
The most common components of green teas are catechin, epicatechin (EC), epicatechin-3-gallate
(ECG), epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG, Figure 8).[100]
Epicatechin has been demonstrated to increase insulin sensitivity in high-fat diet fed mice via
downregulation of inactivators of the insulin receptor signaling pathway, such as c-Jun N-terminal
kinase (JNK), IkB kinase (IKK), protein kinase δ (PKCδ) and protein tyrosine phosphatase 1B
(PTP1B);[101] it is suggested that this may occur via inhibition of NADPH oxidase (and reduction
of superoxide formation) and/or direct binding to NF-κB and inhibition of interaction with DNA.
Similarly, EGCG was shown to modify glucose metabolism by enhancing glucose tolerance and
thereby reducing plasma triglyceride levels in rats. This effect was also postulated to result from
increased expression of glycolytic genes and decreased expression of gluconeogenic genes –
however, no transcription factor targets were proposed, as seen in Figure 9.[102]
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Figure 8. Pro-hypoglycemic catechin metabolites found in teas, in addition to catechin and
catechol.
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Figure 9. The effect of epicatechin on insulin sensitivity through downregulation of inactivators.

Protocatechuic acid (PCA), that we last saw as an intermediate in the metabolism of catechin to
catechol,[37, 38, 103] has been shown to promote pro-hypoglycemic effects and will likely be
produced endogenously with normal consumption of teas or other catechin-containing food
sources. PCA significantly improved glucose tolerance in streptozotocin-induced diabetic
mice.[104] Particularly noteworthy were the decreases in IL-1β, IL-6, and TNF-α; the genes
coding for these inflammatory cytokines are typically under transcriptional control of the same
NF-κB postulated to be inhibited by epicatechin. In a cellular model, omental adipocytes displayed
an increase in glucose uptake via GLUT4 membrane translocation and increased adiponectin
expression following PCA treatment, resulting from activation of the peroxisome proliferatoractivated receptor (PPARγ).[105] Catechins and their catabolites appear to ameliorate glucose
intolerance by regulating enzymes or transcription factors with the underlying theme of decreasing
inflammation, suppressing gluconeogenesis, and enhancing sensitization of insulin receptor
signaling. These promising effects necessitate systematic studies to characterize the structureactivity relationships of catechins and the transcription factors that they activate or inhibit (e.g.
NF-κB, PPARγ).
4.2.2 Oxoguaiacols
A number of compounds present in fragrant, pungent, or otherwise flavourful foods contain
guaiacols (O-methylcatechols) with an alkyl tail that is oxo- or keto-functionalized at the 3-carbon
(Figure 10). These belong to a number of broad families including the capsaicinoids, the
capsinoids, and the curcuminoids (Table 4). In contrast to the clinical “gold standard” antidiabetic
drug metformin, the capsaicinoids and capsinoids typically promote hypertrophy and anabolism –
whereas metformin and adenosine monophosphate-dependent kinase can promote catabolism,
autophagy, and inhibition of biosynthesis[106, 107] – and so the capsaicinoids or some future
pharmacologically-related synthetic analogues offer potentially less damaging therapeutic
alternative. Studies with guaiacol moieties have demonstrated that some elicit pro-hypoglycemic
properties, as guaiacol hydrolysis can produce catechol.[108] As a whole, the capsaicinoids and
the capsinoids seem to have a common cellular target: transient receptor potential cation channel
subfamily V member 1 (TrpV1), a membrane calcium channel [109]. Binding of capsaicin to a site
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on the intracellular leaflet opens the channel and triggers calcium influx. How this improves
glucose tolerance remains to be mechanistically defined – typically, Ca2+ should activate glycogen
phosphorylase rather than synthase, yet the capsaicinoids varyingly promote increased glycogen
content. Found in chili pepper extract, capsaicin (31) is noted for its analgesic properties but often
limited in its pharmaceutical use due to the burning sensation it elicits. Capsinoids are analogues
of capsaicin that lack pungency while often containing the same beneficial properties.[109]
Capsaicin and a related analogue capsiate (32) were both shown to improve glucose tolerance
when administered to high-fat fed diabetic rats, however only capsiate was shown to enhance
hepatic insulin sensitivity during euglycemic hyperinsulinemic clamp. Glucose tolerance was
improved through decreased hepatic PEPCK expression while insulin sensitivity was likely
enhanced via increased expression of GLUT2 and glucokinase which further promoted hepatic
glucose utilization.[110]
Dihydrocapsiate (33), another capsaicin analogue, has also been shown to prevent hyperglycemia
and hyperinsulinemia while improving glucose tolerance in high-fat diet mice. This outcome was
attributed to a combination of improved insulin signaling and the suppression of hepatic
gluconeogenic genes.[111]
Curcumin (34), a common component of turmeric, has been extensively studied for its therapeutic
effects. One study demonstrated that curcumin caused a significant decrease in the mean fasting
blood sugar of type 2 diabetic patients by increasing PPARγ activity and enhancing GLUT2 and
GLUT4 expression.[112] Additionally, curcumin has been shown to increase insulin sensitivity
through increased expression of the adiponectin gene.[113] This molecule, in particular, has
penetrated the popular imagination, although solubility challenges will continue to require the
generation of analogues or drug delivery solutions.[114]
When administered to Sprague-Dawley rats, zingerone (35), a guaiacol found in ginger,[115]
promotes activation of the peroxisome proliferator-activated receptors (PPARs). It was proposed
that this likely occurred via 35 acting as a PPAR substrate agonist due to the observed increased
PPAR DNA binding activity. Upregulated PPAR activity has been previously linked to enhanced
insulin sensitivity. Thus, PPARγ modulation or PPAR agonists may provide a promising method
of insulin resistance reduction.[116]
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Figure 10. Pro-hypoglycemic oxoguaicols and tyrphostins discussed in the review.
4.2.3 Tyrphostins (pro-hypoglycemic)
In contrast to the pro-hyperglycemic tyrphostins, a number of catechol containing tyrphostins elicit
pro-hypoglycemic effects, including tyrphostin 23 (36), which induced a two-fold increase in
glucose consumption when administered to rat astrocyte cultures.[117] This was postulated to
occur via a series of phosphorylation/dephosphorylation events that collectively increased
astrocyte glycolysis and enhanced glycolytic flux. These results were dependent upon the
continued presence of the tyrphostin as removal of the compound diminished the prohypoglycemic effects. Interestingly, the study also examined tyrphostin 25 (T25), a structural
analogue of T23 which lacks the catechol functional group, and noted that it did not accelerate
astrocyte glycolytic flux.
Davoodi-Semiromi and coworkers examined tyrphostin AG490 (37) for its metabolic impact.[118]
This compound has been extensively studied for its potential anti autoimmune disease
properties.[118, 119] AG490 significantly reduced plasma glucose concentration and modulated
the expression of numerous transcription factors associated with diabetes progression in both
human adipocytes and a mouse in vivo model. Further research revealed that this mechanism might
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occur via AG490-induced Jak-Stat signaling inhibition via regulation of PPARγ, ADIPOQ, and
C/EBP.

4.2.4 Miscellaneous
Other studies have focused on the catecholestrogens (4), namely 2-hydroxycatecholestradiol and
4-hydroxycatecholestradiol. Their synergistic effects alongside estradiols in mink uterine
metabolism were explored with results showing a linkage to upregulated glycogen synthase
levels.[120] This resulted in increased uterine glycogen concentrations, with a proposed mechanism
involving phosphorylation and inactivation of the uterine glycogen synthase kinase-3B (GSK-3B).
Gsk-3B inactivation reportedly reduced glycogen synthase inhibition, which resulted in increased
glycogen synthesis and reduced blood glucose levels.[120]
Masoprocol found in creosote contains two catechol moieties. The compound has proposed
antioxidant properties and has been historically used as an antineoplastic agent, mainly to combat
skin cancers, although it may also provide some benefits in treating type 2 diabetes.[121] When
orally administered to hypertriglycemic diabetic rodents, masoprocol reduced serum triglyceride
levels by reducing hepatic triglyceride secretion and increasing peripheral triglyceride clearance
rates.[122] This result may provide ties to hypoglycemic outcomes as high serum triglyceride
levels have been shown to be related to higher insulin resistance and the development of metabolic
syndrome.[123] Masoprocol, by reducing serum triglyceride levels in diabetic rodents, may
counteract emerging insulin resistance and thus promote hypoglycemia, but further research must
be conducted to determine the exact relationship between these two variables.

Table 4. Pro-Hypoglycemic Catechol Moieties
Catechol-containing
compound
Epicatechin
Epigallocatechin3-gallate
Protocatechuic acid

Catechol estrogens
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Effect on carbohydrate metabolism
- downregulation of insulin signaling cascade proteins [101]
- enhancing glucose tolerance and reducing plasma triglyceride levels [102]
- PPARγ increased activity
- increased GLUT4
- increase adiponectin [96, 104]
- increased glycogen concentrations

Masoprocol
Tyrphostin AG490

- Gsk-3B protein inactivation [120]
- reduced high triglyceride concentrations
- reduced insulin resistance [122]
- Jak-Stat signaling inhibition via regulation of PPARγ, ADIPOQ, and C/EBP
transcription factors. [118]

Capsiate

- decreased PEPCK expression
- increased GLUT2 and glucokinase expression [110]

Dihydrocapsiate

- improved insulin signaling [111]

Curcumin

-increased PPARy activity
-increased GLUT2/ GLUT4 expression [112]

Zingerone

- PPAR increased activity
- receptor agonist [115]

Tyrphostin 23

-glycolytic flux increased via phosphorylation [117]

5. Comparative discussion of hypoglycemic and hyperglycemic catechol-containing
compounds and conclusion
Given the diverse effects of catechols on metabolic modulation, coupled with their undefined
mechanisms of action, it is of critical importance to correlate the unique structural features of
different catechols with their metabolic outcomes. What we clearly have is an interplay between
the actions of the individual molecules on target receptors, and the actions of their catechol
metabolite on insulin sensitization. The careful balancing of these effects must be considered.
Pro-hyperglycemic moieties generally incorporate amine groups, and while their mechanisms of
action vary, many involve agonism or antagonism of receptor signaling cascades or enzymatic
activity. These receptors include β-adrenergic receptors, α-adrenergic receptors, and IGF-I
receptors. Many of the enzymes involved appeared to be related to glycogen metabolism, namely
glycogen phosphorylase and glycogen synthase. Regardless of their exact mechanism, all of these
moieties resulted in elevated plasma glucose and decreased insulin sensitivity.
Conversely, many pro-hypoglycemic moieties lack nitrogen and are instead polyphenolics and
flavonoid derivatives. Catechols bound to a fused ring system (i.e. estrogen) and guaiacol moieties
are also a common motif seen in pro-hypoglycemic compounds. This structural trend appears to
be more complex when compared to pro-hyperglycemic compounds. Many pro-hypoglycemic
compounds act through gene regulation and receptor translocation. Some common trends include
increased PPARγ activity and increased GLUT4/GLUT2 expression. In addition to this, regulation
of insulin signaling proteins and carbohydrate metabolic modulation were also common. These
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mechanisms result in decreased plasma glucose levels and increased insulin sensitivity. Catechin
and its related compounds found in green tea are a likely useful target for a diet adjustment to work
with a catechol-producing probiotic as their activity is synergistic with the desired effect. These
are also among the most common catechins present in the diet and so this beneficial effect should
dominate.
Continued analysis of the structural and mechanistic trends among pro-hyperglycemic and prohypoglycemic catechol moieties may provide further insight into the features required to elicit
each response and provide novel alternative methods to combat type 2 diabetes and other metabolic
syndrome disorders and help unravel the mechanistic role of the catechols beyond their simple
inherent antioxidant activity. However, it appears that for applications involving catechol
generation, it seems wisest to focus on mechanisms that exploit the pro-hypoglycemic sources,
especially catechin/epicatechin-rich teas. The genetic engineering of a Lactobacillus with an
increased capacity to convert these catechins to catechol could prove a potentially useful tool for
the probiotic delivery of this nutraceutical.
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